Amneal Pharmaceuticals (AMRX) Goldman Sachs 46th Annual Global Healthcare Conference summary

Strategic vision and growth priorities

• Focus on expanding biosimilars, aiming to be a top five global player within 5–7 years, with a pipeline of 15–25 assets and annual additions of 3–4 products.

• Significant growth expected in the GLP-1 segment, leveraging the Metsera partnership and targeting large patient populations, especially in India.

• Specialty drugs and affordable innovations prioritized, with R&D budget capped at $200 million annually and focus on assets generating $100–$500 million in revenue.

• Continued commitment to core generics business, with 280 medicines and plans to offset price erosion through volume and new launches.

• Vertical integration in biosimilars targeted through likely acquisition of Kashiv BioSciences, bringing R&D and manufacturing in-house.

Market environment and policy outlook

• U.S. generics market is experiencing 4–6% price erosion, but growth is driven by increased volume and more loss of exclusivity (LOE) opportunities.

• Government incentives and faster FDA approvals are supporting industry expansion, with biosimilars and small molecules both poised for growth.

• Ongoing lobbying against pharma tariffs, with alternative proposals for essential medicines procurement to ensure supply chain security.

• High U.S. manufacturing footprint (70%) positions the company to benefit if tariffs are imposed, with flexibility to restart idle plants if needed.

Biosimilars and GLP-1 strategy

• Biosimilars market expected to see major revenue growth from 2027–2032, with focus on less competitive products and both PBM and buy-and-bill channels.

• Partnership with Metsera provides manufacturing and commercialization rights in 20 countries, with significant opportunity in India and ongoing efforts to improve peptide manufacturing yields.

• Supply constraints in peptide manufacturing anticipated, especially for oral GLP-1s, due to high API requirements.